Literature DB >> 29489018

Use of the CRISPR/Cas9-based epigenetic gene activation system In Vivo: A new potential therapeutic modality.

Samar H Ibrahim1,2, Keith D Robertson3.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29489018      PMCID： PMC6113124          DOI： 10.1002/hep.29860

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  8 in total

1.  In Vivo Target Gene Activation via CRISPR/Cas9-Mediated Trans-epigenetic Modulation.

Authors:  Hsin-Kai Liao; Fumiyuki Hatanaka; Toshikazu Araoka; Pradeep Reddy; Min-Zu Wu; Yinghui Sui; Takayoshi Yamauchi; Masahiro Sakurai; David D O'Keefe; Estrella Núñez-Delicado; Pedro Guillen; Josep M Campistol; Cheng-Jang Wu; Li-Fan Lu; Concepcion Rodriguez Esteban; Juan Carlos Izpisua Belmonte
Journal:  Cell       Date:  2017-12-07       Impact factor: 41.582

Review 2.  CRISPR/Cas9: at the cutting edge of hepatology.

Authors:  Francis P Pankowicz; Kelsey E Jarrett; William R Lagor; Karl-Dimiter Bissig
Journal:  Gut       Date:  2017-05-09       Impact factor: 23.059

3.  A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.

Authors:  Martin Jinek; Krzysztof Chylinski; Ines Fonfara; Michael Hauer; Jennifer A Doudna; Emmanuelle Charpentier
Journal:  Science       Date:  2012-06-28       Impact factor: 47.728

4.  Epigenetic modifications as new targets for liver disease therapies.

Authors:  Müjdat Zeybel; Derek A Mann; Jelena Mann
Journal:  J Hepatol       Date:  2013-06-04       Impact factor: 25.083

5.  Nucleosomes impede Cas9 access to DNA in vivo and in vitro.

Authors:  Max A Horlbeck; Lea B Witkowsky; Benjamin Guglielmi; Joseph M Replogle; Luke A Gilbert; Jacqueline E Villalta; Sharon E Torigoe; Robert Tjian; Jonathan S Weissman
Journal:  Elife       Date:  2016-03-17       Impact factor: 8.140

Review 6.  CRISPR-Mediated Epigenome Editing.

Authors:  Paul Enríquez
Journal:  Yale J Biol Med       Date:  2016-12-23

Review 7.  Epigenetics in liver disease: from biology to therapeutics.

Authors:  Timothy Hardy; Derek A Mann
Journal:  Gut       Date:  2016-09-13       Impact factor: 23.059

8.  dCas9-based epigenome editing suggests acquisition of histone methylation is not sufficient for target gene repression.

Authors:  Henriette O'Geen; Chonghua Ren; Charles M Nicolet; Andrew A Perez; Julian Halmai; Victoria M Le; Joel P Mackay; Peggy J Farnham; David J Segal
Journal:  Nucleic Acids Res       Date:  2017-09-29       Impact factor: 19.160
  8 in total
  1 in total

1.  Multifunctional CRISPR-Cas9 with engineered immunosilenced human T cell epitopes.

Authors:  Shayesteh R Ferdosi; Radwa Ewaisha; Farzaneh Moghadam; Sri Krishna; Jin G Park; Mo R Ebrahimkhani; Samira Kiani; Karen S Anderson
Journal:  Nat Commun       Date:  2019-04-23       Impact factor: 14.919
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.